What Zoetis's Quarter ended Sep 30, 2026 10-Q says: 7 signals
Zoetis filed its latest 10-Q with the SEC on Nov 5, 2026. It discusses bookings decline, international growth and margin pressure.
Public (ZTS)Pharmaceutical Manufacturing10,000+ employeeszoetis.comLinkedIn
Get Zoetis' live signals in Claude or ChatGPT, or by API
What changed at Zoetis this week? Use Autobound signals for zoetis.com.- Filed
- Nov 5, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 18
Source: Autobound Signal API · 80 signals tracked for Zoetis · updated
10-Q · latest 10
What Zoetis's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 7 signals
Zoetis began utilizing certain aspects of a new enterprise resource planning system during the quarter ended September 30, 2026, which over the next several years will replace its existing core financial systems.
enterprise resource planningERP
Zoetis reports $142M in restructuring and acquisition charges across nine months of 2026
Restructuring charges and certain acquisition and divestiture-related costs totaled $142 million for the nine months ended September 30, 2026, driven by employee termination costs and asset impairments under a comprehensive cost and productivity program.
Zoetis incurred restructuring charges and acquisition and divestiture-related costs of $43 million in the quarter and $142 million year-to-date driven by employee termination costs and asset impairments under a comprehensive cost and productivity program.
Zoetis launches monoclonal antibody pain products Lenivia and Portela in international markets
Zoetis launched Lenivia and Portela, long-acting monoclonal antibody pain products, supporting companion animal sales internationally during Q3 2026.
Zoetis cost of sales increases to 29.2% of revenue in Q3 2026
Cost of sales as a percentage of revenue rose to 29.2% from 28.8% in the prior year period, driven by higher inventory charges, lower net price realization, and unfavorable product mix.
29.2%
cost of sales as a percentage of revenue
Zoetis volume declines 1% in Q3 and 2% year-to-date across key franchises
Operational revenue was impacted by key franchise volume decreases of approximately 1% in the quarter and 2% over the first nine months of 2026, with U.S.
-1%
volume decrease from key franchises
International segment revenue increases 4% to $1,116 million in Q3 2026
International operating revenue grew 4% (3% operational) to $1,116 million for the quarter ended September 30, 2026, driven by a 6% operational rise in livestock products.
4%
growth in International segment revenue
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 7 signals
Zoetis implements multi-year migration to update ERP to new fully cloud-based system
Zoetis is executing a phased multi-year implementation to replace its existing ERP system with a new fully cloud-based system, prompting the elimination of a one-month reporting lag across international subsidiaries as of January 1, 2026.
ERPcloud-based system
Restructuring charges and certain acquisition and divestiture-related costs totaled $77 million for the three months ended June 30, 2026, driven by employee termination costs under a comprehensive cost and productivity program.
Zoetis launches Lenivia and Portela monoclonal antibody pain products in international markets
Zoetis launched Lenivia and Portela, long-acting monoclonal antibody pain products, driving companion animal operational revenue growth internationally.
mAbmonoclonal antibody
Earlier 10-Q filings
- 10-Q · Quarter ended Mar 31, 2026Filed · 4 signalsSEC EDGAR
Showing 10 of 18 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Zoetis earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Dermatology share loss slowed to 4 points in quarterThe key dermatology portfolio saw global revenue decline 16% to $396 million, including a 13% decline in the U.S. driven by market share losses in Apoquel against new competitive entrants. Promotional defense investments helped moderate U.S. dermatology share loss to 4 points in Q3 from 7 points in Q2. | |
| Livestock revenue grows 7% to $797M across international marketsLivestock revenue rose 7% globally to $797 million, serving as a bright spot offset to companion animal weakness. International livestock surged 9% to $531 million, led by cattle strength and fish performance in Norway, while U.S. livestock grew 5% to $266 million. | |
| Full-year adjusted net income guidance raised to $2.64BManagement raised full-year adjusted net income guidance to $2.60B-$2.64B and adjusted diluted EPS guidance to $6.25-$6.35. Revenue guidance was narrowed toward the high end at $9.22B-$9.32B. | |
| Jay Saccaro appointed as Chief Financial Officer and COOJay Saccaro attended his first earnings call as Chief Financial Officer and Chief Operating Officer, initiating a comprehensive review of the company's cost structure and operational guidance metrics. Executive transitions at the CFO/COO level frequently trigger reviews of operating expenses, vendor contracts, and enterprise software stacks. | |
| Convenia RTU approved in US and launching in CanadaConvenia RTU for dogs has secured regulatory approval in the U.S. and is set to launch in Canada, offering up to 14 days of treatment via a single injection. The company is actively introducing lifecycle innovations to defend against generic pressure on legacy Convenia and Cerenia. | |
| Increased R&D spending on data and digital initiativesAdjusted R&D spending totaled $174 million in Q3, reflecting targeted investments in data and digital initiatives alongside pipeline project progression. These tech investments were offset by corporate cost and productivity savings in professional services and incentive compensation. |
Signal API · MCP
Track Zoetis with the Signal API
One POST /v1/companies/enrich call with zoetis.com returns Zoetis 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"zoetis.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Zoetis 10-Q
When did Zoetis file its latest 10-Q?
What did Zoetis disclose in its latest 10-Q?
What did Zoetis say on its recent earnings calls?
Where can I read Zoetis's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .